¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"systemic inflammatory response syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 6
¿µ¹® respiratory distress syndrome(RDS) ÇÑ±Û È£Èí°ï¶õÁõÈıº
¼³¸í   
  ÆóÆ÷¿Í Æó¸ð¼¼Ç÷°ü »çÀÌ¿¡ ºÎÁ¾À¸·Î ÀÎÇÑ È®»ê´É °¨¼Ò·Î È£Èí°ï¶õ°ú Ã»»öÁõÀ» º¸À̴ »óÅ·Π°¨¿°, ¼ö¼ú, ¿Ü»ó µî ¸ðµç Á¾·ùÀÇ ½ºÆ®·¹½º»óȲ¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. Ä¡·á´Â ¼±Çà ¿äÀÎÀÇ ±³Á¤°ú ÀûÀýÇÑ Ç÷¾×³» »ê¼Ò³óµµ À¯ÁöÀÌ´Ù.
¿µ¹® acquired immunodeficiency syndrome ÇÑ±Û ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
¼³¸í   
  Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º(HIV)¿¡ ÀÇÇÏ¿© ¸é¿ª ¼¼Æ÷°¡ ÆÄ±«µÊÀ¸·Î½á ÀÎüÀÇ ¸é¿ª´É·ÂÀÌ ±Øµµ·Î ÀúÇϵǾ´¿øÃ¼¿¡ ´ëÇÏ¿© ¹«¹æºñ »óÅ¿¡ À̸£´Â º´. ¿¡ÀÌÁî ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â¸ç, 1981³â ¹Ì±¹¿¡¼­ Ã³À½ º¸°íµÇ¾ú´Ù. ÃÖÃÊ °¨¿°À¸·ÎºÎÅÍ Áõ»óÀÌ ³ªÅ¸³ª±â±îÁö´Â Æò±Õ 10³â Á¤µµ °É¸®¸ç »ç¸Á·üÀÌ ´ë´ÜÈ÷ ³ô´Ù. ¼ºÀû Á¢ÃË, ¿À¿° ÁÖ»ç±â »ç¿ë, ¿À¿° Ç÷¾× ¹× Ç÷¾× Á¦Á¦ »ç¿ë, ¿¡ÀÌÁî »ê¸ð·ÎºÎÅÍ ¼öÁ÷°¨¿° µûÀ§¿¡ ÀÇÇÏ¿© °¨¿°µÈ´Ù. °¨¿° ÈÄ Àϰú¼ºÀ¸·Î °¨±â¿Í °°Àº Áõ»óÀ» º¸À̸砹ÙÀÌ·¯½ºÇ÷ÁõÀ¸·Î µÇÁö¸¸ ¹ÙÀÌ·¯½º´Â °¨¼ÒµÇ°í 6~8ÁÖ ÈÄ¿¡´Â Ç×ü°¡ ¾ç¼ºÀ¸·Î µÈ´Ù. 6~10³â Á¤µµÀÇ ¹«ÁõÈļº º¸±Õ±â°£À» Áö³ª¼­ ¿¡ÀÌÁî°ü·ÃÁõÈıº(AIDS related syndrome)À¸·Î µÈ´Ù. ÀúÇ×·ÂÀÇ °¨¼Ò, ¸²ÇÁÀýºñ´ë, Ã¼Áß°¨¼Ò, ¹ß¿­, ¸¸¼º¼³»ç°¡ À̾îÁø´Ù. ±× ÈÄ ¿¡ÀÌÁî·Î µÇ¸ç, ÆóÆ÷ÀÚÃæÆó·Å µîÀÇ ¿øÃ溴, Ä­µð´Ù µîÀÇ Áø±ÕÁõ, Ç츣Æä½º¹ÙÀÌ·¯½º±º µîÀÇ ±âȸ°¨¿°ÀÌ À̾îÁø´Ù. ¶ÇÇÑ Ä«Æ÷½ÃÀ°Á¾, ¸²ÇÁÁ¾ µîÀ» º´¹ßÇØ¼­ »ç¸ÁÇÑ´Ù. ¹ÙÀÌ·¯½ºÀÇ ³úÁ¶Á÷³» Áõ½ÄÀ¸·Î Ä¡¸Å¸¦ ÀÏÀ¸Å³ ¼öµµ ÀÖ´Ù. HIV-1Àº 10³â°£¿¡ »ç¸Á·üÀÌ 90%, HIV-2´Â 10%ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • response modulation
    ¹ÝÀÀÁ¶Á¤
  • response prevention
    ¹ÝÀÀ¿¹¹æ
  • response rate
    ¹ÝÀÀ·ü
  • reticulocyte response
    ±×¹°ÀûÇ÷±¸¹ÝÀÀ, ¸Á»óÀûÇ÷±¸¹ÝÀÀ
  • startle response
    ³î¶÷¹ÝÀÀ
  • startle response audiometry
    ³î¶÷¹ÝÀÀû·Â°Ë»ç
  • stereotyped response
    ÀÚµ¿¹Ýº¹¹ÝÀÀ, »óµ¿¹ÝÀÀ
  • stimulus response assessment
    ÀڱعÝÀÀÆò°¡
  • subthreshold response
    ¹®ÅιعÝÀÀ
  • secondary evoked response
    ÀÌÂ÷À¯¹ß¹ÝÀÀ
  • secondary immune response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • sensitization response
    ¹Î°¨È­¹ÝÀÀ
  • shortening response
    ´ÜÃà¹ÝÀÀ
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Sjogren syndrome
    ¼î±×·»ÁõÈıº
  • Stevens-Johnson syndrome
    ½ºÆ¼ºì½ºÁ¸½¼ÁõÈıº
  • subacromial syndrome
    ºÀ¿ì¸®¹ØÁõÈıº, °ßºÀÇÏÁõÈıº
  • sudden infant death syndrome
    ¿µ¾Æ±Þ»çÁõÈıº
  • superior vena caval syndrome
    À§´ëÁ¤¸ÆÁõÈıº, »ó´ëÁ¤¸ÆÁõÈıº
  • tarsal tunnel syndrome
    ¹ß¸ñ±¼ÁõÈıº, Á·±Ù°üÁõÈıº
  • testicular feminization syndrome
    °íȯ¿©¼ºÈ­ÁõÈıº
  • thoracic outlet syndrome
    °¡½¿¹®ÁõÈıº, Èä°ûÃⱸÁõÈıº
  • Turner's syndrome
    ÅͳÊÁõÈıº
  • withdrawal syndrome
    ±Ý´ÜÁõÈıº
  • Wolff-Parkinson White syndrome
    ¿ùÇÁÆÄŲ½¼È­ÀÌÆ®ÁõÈıº
  • WPW syndrome
    (¢¡Woff Parkinson White syndrome) ¿ùÇÁÆÄŲ½¼È­ÀÌÆ®ÁõÈıº
  • X syndrome
    ÁõÈıº¿¢½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£
  • inverse response
    ¿ª¹ÝÀÀ
  • lytic response
    ¿ëÇØ¹ÝÀÀ
  • memory immune response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • microphonic response
    ¸¶ÀÌÅ©·ÎÆù¹ÝÀÀ
  • myotactic response
    ±ÙÀ°½ÅÀü¹ÝÀÀ
  • response modulation
    ¹ÝÀÀÁ¶Á¤
  • placebo response
    ¼ÓÀÓ¾à¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • pyramidal tract response
    ÇǶó¹Ô·Î¹ÝÀÀ, Ãßü·Î¹ÝÀÀ
  • response prevention
    ¹ÝÀÀ¿¹¹æ
  • response
    ¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ
  • response rate
    ¹ÝÀÀ·ü
  • response set
    ¹ÝÀÀ¼¼Æ®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Alstr ms syndrome
    ¾Ë½ºÆ®·Ý ÁõÈıº
  • Angelmans syndrome
    ¾Þ°Ö¸¸ ÁõÈıº
  • Aperts syndrome
    ¿¡ÀÌÆÛÆ® ÁõÈıº
  • Aperts syndrome => acrocephalosyndactyly
    ¸»´Ü µÎÇÕÁöÁõ
  • Aschers syndrome
    ¾Ö¼ÅÁõÈıº
  • Aspergers syndrome
    ¾Æ½ºÆÛ°Å ÁõÈıº
  • Axenfeld syndrome
    ¾Ç¼¾ÆçÆ®ÁõÈıº
  • B-K mole syndrome
    B-K¸ð¹Ý ÁõÈıº
  • Bantis syndrome
    ¹ÝƼÁõÈıº.
  • Bare lymphocyte syndrome
    ¹«Ç¥Áö¸²ÇÁ±¸ÁõÈıº
  • Behcets syndrome
    º£Ã¼Æ® ÁõÈıº.
  • Behcets syndrome
    º£Ã¼Æ® ÁõÈıº
  • Benedikts syndrome
    º£³×µñÆ®ÁõÈıº
  • Blackfan-Diamond syndrome
    ºí·¢ÆÇ-´ÙÀ̾ƸóµåÁõÈıº
  • Bloom syndrome
    ºí·ç¿òÁõÈıº(¡­ñøý¦ÏØ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • systemic nodular panniculitis
    Àü½Å(¼º)°áÀý¼º Áö¹æÃþ¿°
  • systemic nodular periarteritis
    Àü½Å °áÀý µ¿¸Æ ÁÖÀ§¿°
  • systemic reaction
    Àü½Å¹ÝÀÀ(îïãóÚãëë).
  • systemic reaction
    Àü½Å¹ÝÀÀ(îïãóÚãëë)
  • systemic scleroderma
    Àü½Å¼º °æÇÇÁõ(¡­Ìã ù«ñø)
  • systemic sclerosis
    Àü½Å¼º °æÈ­(Áõ)
  • systemic sclerosis [=scleroderma]
    Àü½Å¼º°æÈ­Áõ[= °æÇÇÁõ]
  • systemic therapy
    Àü½Å Ä¡·á
  • systemic treatment
    Àü½Å¿ä¹ý(îïãóèþÛö).
  • age-response function
    ¿¬·É¹ÝÀÀÇÔ¼ö
  • alerting response
    °¢¼º¹ÝÀÀ(ÊÆá¥Úãëë)
  • allergic response
    ¾Ë·¹¸£±â¹ÝÀÀ, °ú¹Î¹ÝÀÀ
  • analytical response detection
    ºÐ¼®¹ÝÀÀ°¨Áö
  • anamnestic response
    ¸é¿ª[ÇÐÀû]±â¾ï[Çö»ó]¹ÝÀÀ
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
IR drop of voltage across a resistor produced by a current; ileal resection; immune response; immunizat...
MLR mean length response; middle latency response; mixed lymphocyte reaction
PR by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr...
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
SER sebum excretion rate; sensitizer enhancement ratio; sensory evoked response; service; smooth endopla...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
NSAID non steroidal anti-inflammatory agents
NSAI Non-steroidal anti-inflammatory
NSAIA Non-steroidal anti-inflammatory agents
PID Pelvic Inflammatory Disease
IIM idiopathic inflammatory myopathy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sensitization response
    °¨ÀÛ ¹ÝÀÀ
  • stimulus response assessment
    ÀÚ±Ø ¹ÝÀÀ Æò°¡
  • thermal camera time response
    ¿­ Ä«¸Þ¶ó ½Ã°£ ¹ÝÀÀ
  • unconditioned response
    ¹«Á¶°Ç ¹ÝÀÀ
  • wide dynamic range response characteristics
    ±¤µ¿¹üÀ§ ¹ÝÀÀ Ư¡, ±¤µ¿Àû ¹üÀ§ ¹ÝÀÀ Ư¡
  • A-V syndrome
    A-V ÁõÈıº
  • Aarskog syndrome
    ¾Æ¸£½ºÄÚ±× ÁõÈıº
    À¯Àü¼º ÁõÈıºÀÇ Çϳª·Î X-¿¬°ü¼º ÇüÁú·Î À¯ÀüµÈ´Ù. Ư¡À¸·Î´Â ¾È±¸ °Ý¸®Áõ, ³ÐÀº À­ ÀÔ¼ú, ¼î¿Ã, ÀÛÀº ¼Õ µîÀÌ ÀÖ´Ù. ¾È¸é ¼º±â Çü¼º Àå¾Ö
  • Aase syndrome
    ¾ÆÁî ÁõÈıº
    °æ¹ÌÇÑ ¼ºÀå Áö¿¬, ÀúÇü¼º ºóÇ÷, ´Ù¾çÇÑ ¹éÇ÷±¸ °¨¼ÒÁõ, ¼¼ °³·Î °¥¶óÁø ¾öÁö¹ß°¡¶ô, Á¼Àº ¾î±ú, ´ÊÀº õ¹® Æó¼â, ¾ðûÀÌ, ±¸°³ ÆÄ¿­, ¸Á¸·º´Áõ µîÀ» Ư¡À¸·Î ÇÏ´Â ÁõÈıºÀ¸·Î¼­ ¿­¼ºÀ¸·Î À¯ÀüµÇ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù.
  • abnormal laterality syndrome
    ÁÂ¿ì ºñ´ëĪ ÀÌ»ó ÁõÈıº
    ½ÉÀå¿¡¼­ Á¤»óÀûÀÎ ÁÂ¿ì ´ëĪÀÌ µÚ¹Ù²î°Å³ª ºÒ¿ÏÀüÇÑ °æ¿ì·Î¼­, ÁÂÃøÀ̳ª ¿ìÃøÇüÀ¸·Î ´ëĪÀÎ °æ¿ì°¡ ÀÖ°í À̵鿡¼­ ¿©·¯ °¡Áö ½ÉÀå ±âÇüÀÌ µ¿¹ÝµÇ´Âµ¥ ÀÌ·¯ÇÑ °æ¿ì¸¦ ½ÉÀåÀÇ ÁÂ¿ì ºñ´ëĪ ÀÌ»ó ÁõÈıºÀ̶ó ÇÑ´Ù. À̵é Áúȯ¿¡¼­´Â ½ÉÀå »Ó ¾Æ´Ï¶ó ÁÖ ±â°üÁö¿Í »óÆóµ¿¸ÆÀÇ À§Ä¡ °ü°è ¹× ÆóÀÇ ºÐ¿±, °£°ú ºñÀåÀÇ ÇüÅ ¹× À§Ä¡°¡ ´Þ¶óÁö¸ç ƯÈ÷ ºñÀåÀÌ ¾ø´Â ¹«ºñÁõ
  • absent pulmonary valve syndrome
    Æó µ¿¸Æ ÆÇ °á¿© ÁõÈıº
    ´Üµ¶À¸·Î ÀϾ´Â °æ¿ì´Â ±ØÈ÷ µå¹°¸ç, ½É½Ç Áß°Ý °á¼Õ, ¿ì½Ç ´©µÎºÎ ÇùÂø¿¡ ÇÕº´ÇÏ´Â °æ¿ì°¡ ºñ±³Àû ¸¹´Ù. Áï Fallot 4ÁõÈÄÀÇ ÇÕº´ ±âÇüÀ¸·Î ³ªÅ¸³­´Ù. ÀÌ °æ¿ì ÁÂ¿ì Æóµ¿¸ÆÀÇ È®´ë, ¥±À½ Æóµ¿¸Æ ¼ººÐÀÇ ¿ÏÀü ¼Ò½Ç, ÇÇÄ¡°¡ ³·Àº È®Àå±â ÀâÀ½À» ³ªÅ¸³½´Ù. À̰ÍÀ» µ¿¹ÝÇÑ Fallot 4ÁõÈÄ´Â À¯¾Æ±â¿¡ ¿ïÇ÷¼º ½ÉºÎÀüÀ» ÀÏÀ¸Å°±â ½±´Ù.
  • absent testes syndrome
    °íȯ °á¿© ÁõÈıº
  • abstinence syndrome
    ±Ý´Ü ÁõÈıº
  • acid aspiration syndrome
    À§»ê ÈíÀÔ ÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª °áÇÌ ÁõÈıº
    1. ÇöÀúÇÑ ¸é¿ª °áÇ̰ú ÇÔ²² ±âȸ°¨¿°, ¼Ó¹ß¼º ¾Ï ¹× ½Å°æ°è Áõ¼¼°¡ µ¿¹Ý. ¹ÙÀÌ·¯½º ÀÚü¿¡ ÀÇÇÑ º´º¯°ú ¸é¿ª´É·Â ÀúÇÏ¿¡ µû¸¥ ±âȸ °¨¿° µîÀÇ ÀÌÂ÷Àû º´º¯ÀÇ µÎ °¡Áö·Î ´ëº°. HIV¿¡ ÀÇÇØ ¹ß»ýµÇ´Â ÁúȯÀ¸·Î ½Å°æ°è°¡ Áß¿ä Ç¥ÀûÁß Çϳª. ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ »ç¶÷ÀÇ 40% Á¤µµ°¡ Áúº´ÀÌ ¹ß»ý. ¹ÙÀÌ·¯½ºÀÇ Á÷Á¢ÀûÀÎ ¿µÇâ¿¡ ÀÌÇÑ º´º¯À¸·Î´Â ¸²ÇÁ±¸¼º ¼ö¸·¿°°ú HIV ³ú¿° µîÀÌ ÀÖÀ½. 2. ÈÄõ¼º ¸é¿ª°áÇÌÁõ. Àΰ£ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
conditioned response A response already in an individual's repertoire but which, through repeated pairings with its natural stimulus, has been acquired or conditioned anew to a previously neutral or conditioned stimulus.
See: conditioning.
Compare: unconditioned response.
(05 Mar 2000)
Cushing response A rise in systemic blood pressure when the intracranial pressure acutely increases, usually in excess of 50% of the systolic arterial pressure.
Synonym: Cushing effect, Cushing response.
(05 Mar 2000)
primary antibody response <immunology> Antibodies made upon first exposure to an antigen, mostly of the class IgM.
(05 Mar 1998)
primary immune response <immunology> The immune response to the first challenge by a particular antigen. Usually less extensive than the secondary immune response, being slower and shorter lived with smaller amounts of lower affinity antibody being produced.
(18 Nov 1997)
heat-shock response <cell biology> A constellation of responses that occur when an organism is exposed to excessive heat and other environmental stresses. Responses include synthesis of some proteins, repression of other proteins, and expression of new proteins.
(12 Dec 1998)
heat-shock response element <cell biology, protein> The nucleotide sequence, CNNGAANNTCCNG, which is in the promoter region of the heat-shock genes. When the animal is exposed to certain types of stress such as a sudden rise in temperature, the first thing that happens to activate these genes is the binding of the HSE by a transcriptional enhancer protein.
(09 Oct 1997)
Henry-Gauer response Inhibition of antidiuretic hormone secretion due to a rise in atrial pressure which stimulates atrial stretch receptors.
(05 Mar 2000)
satiety response Behavioural response associated with the achieving of gratification.
(12 Dec 1998)
psychogalvanic response A change in electrical resistance of the skin, occurring in emotion and in certain other conditions.
(12 Dec 1998)
secondary antibody response An antibody made upon second (subsequent) exposure to an antigen, mostly of the class IgG.
(09 Oct 1997)
secondary immune response The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen.
(18 Nov 1997)
humoral immune response <immunology> Those immune responses mediated by antibody.
(06 Mar 1998)
serum response element Dyad symmetry element bound by serum response factor to control the expression of c fos.
(18 Nov 1997)
serum response factor Transcription factor that binds to the serum response element upstream of the site of transcription initiation of genes such as c fos.
(18 Nov 1997)
signal response coupling The cascade of processes by which an extracellular signal (typically a hormone or neurotransmitter) interacts with a receptor at the cell surface, causing a change in the level of a second messenger for example calcium or cyclic AMP) and ultimately effects a change in the cells functioning (for example: triggering glucose uptake or initiating cell division). Can also be applied to sensory signal transduction, for example of light at photoreceptors.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á